ClinicalTrials.gg
RecruitingNCT06103760PoETUpdated Aug 12, 2026

Positioning of Esketamine Treatment in the Real-world Management of Depression

A Phase 4 interventional study of Esketamine Nasal Spray [Spravato] in Major Depressive Disorder, sponsored by Royal North Shore Hospital. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Royal North Shore Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.

Planned enrollment
7th of 17
162 · median 147
Started
2023
with 1 other
Phase 4
4 of 17
2 open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Royal North Shore Hospital

Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 7th largest by planned enrollment, is one of 2 that started in 2023, is one of 4 in phase 4, and was the 16th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing esketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are:

  • to investigate whether Esketamine is effective when added to ongoing antidepressant treatment
  • to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice

Participants will:

  • attend the clinic for supervised self-administration of intranasal Esketamine treatment
  • be observed for 2 hours following Esketamine administration including blood pressure monitoring
  • be asked to complete a battery of questionnaires
  • be reimbursed for travel expenses
Read the detailed description

Depression is a common mental illness, and it is one of the leading causes of disease burden worldwide. Fortunately, there are many effective treatments available for depression, including lifestyle changes, psychological treatments, and medications such as antidepressants. However, not all patients will respond to the first treatment prescribed. Some patients may only experience a 'partial response', where a few treatments help their depression somewhat, but they do not achieve a full recovery. Currently, the reasons why some patients do not respond, or only experience a partial response to an antidepressant, is not fully understood.

Recently, researchers have been investigating new medications that may help patients recover from depression. One of these new medications is Esketamine, which is a relatively new molecule derived from a drug called Ketamine - an anaesthetic that has been used medically for decades. Researchers have been investigating the antidepressant properties of Ketamine for a long time. It is thought that Ketamine, and its derivative, Esketamine, help to treat depression for a number of reasons. However, it is not yet known which patients benefit most from Esketamine when used in conjunction with conventional antidepressants. In addition, we do not yet understand how the effect of Esketamine is impacted by other treatments that a patient may be taking for their depression. Finally, it has not yet been investigated how patients with a partial response to an antidepressant will benefit from adding Esketamine to their therapeutic regimen without switching to a new baseline antidepressant. Therefore, there are two principle aims of this study 1) to investigate whether Esketamine is effective when added to ongoing antidepressant treatment and 2) to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18-65 years old
  2. Diagnosis of Major Depressive Disorder (MDD)
  3. Currently depressed
  4. Had an inadequate response to 2 or more courses of antidepressants (of adequate dose and duration)
  5. Be maintained on their current antidepressant medication or psychological therapy at the time of enmrolment
  6. Able to understand and provide

Exclusion criteria

Exclusion Criteria:

  1. Concurrent diagnoses:

    • Participants with other '' (DSM-5) e.g., current substance misuse disorder, bipolar disorder, schizophrenia
    • Participants who are unable to understand the study and therefore unable to provide
  2. Pregnancy:

    • Participants who are pregnant and/or breastfeeding
    • Participants who are not willing to avoid pregnancy for themselves or their partners during the study by using effective methods
  3. Current medications:

    • Participants taking a total daily dose of benzodiazepines greater than the equivalent of 6mg/day of lorazepam
    • Participants on complementary and alternative medicine therapies i.e., St John's wort, Chinese medicines, and various herbal and homeopathic treatments
  4. Stimulants

    • Participants taking stimulants such as methylphenidate, amphetamine, and dextroamphetamine for a diagnosis such as ADHD can still have Esketamine provided they do not continue taking stimulants concurrently for the duration of the study.
    • Concurrent use is excluded due to the synergistic effect with Esketamine that can cause increased blood pressure.
  5. Medical history:

    • Participants with current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
    • Participants with a history of uncontrolled hypertension
    • Participants with uncontrolled diabetes mellitus
    • Participants with aneurysmal vascular disease including thoracic and abdominal aorta, intracranial and peripheral arterial vessels, or arteriovenous malformation, intracerebral haemorrhage
    • Participants with untreated glaucoma, current penetrating or perforating eye injury, brain injury, hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other condition associated with increased intracranial pressure or increased intraocular pressure or planned eye surgery
    • Participants who are currently receiving electroconvulsive therapy (ECT) or have received ECT in the past month.
  6. Substance Misuse History:

    • Participants who have ever had a substance misuse disorder involving any of the following over their lifetime: ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-methamphetamine (MDMA), or other hallucinogen use history
    • Participants with to Esketamine, Ketamine, or any of the
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Other
    Participants with Major Depressive Disorder

    Intranasal esketamine to be self-administered by participants under direct supervision of a healthcare professional. First initial dose is 56mg and subsequent doses will be 56mg or 84mg. Esketamine will be administered twice weekly for weeks 1-4, once weekly for weeks 5-8, and once weekly/once fortnightly/once monthly as clinically indicated for weeks 9-25. After each treatment phase, participants will be re-assessed through a comprehensive battery of assessments and dose adjustments will be performed by the study psychiatrist base on tolerability, treatment response, and ongoing consent.

    Drug: Esketamine Nasal Spray [Spravato]

Interventions

  • DrugEsketamineStudies of EsketamineEsketamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.

    Also known as: Spravato

06

What researchers measure

Primary outcomes

  1. Percentage of treatment responders determined by a 50% reduction on the Hamilton Depression Rating Scale (HAM-D) 17-Item scoring.

    Hamilton Depression Rating Scale (HAM-D) 17-Item scoring

    Time frame: At the end of week 4

  2. Mean depression score on the Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item.

    Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item.

    Time frame: Baseline, at the end of weeks 1,2,3, and 4 (primary time point); and further after week 8 and week 12 after Esketamine was commenced.

  3. Global functioning determined by Clinical Global Impression (CGI) score.

    Clinical Global Impression (CGI)

    Time frame: Baseline, week 1, week 2, week 3, week 4 (primary time point), week 8 and week 12 after Esketamine was commenced.

Secondary outcomes

  1. Change in mood symptom scores assessed using the visual analogue scale (self-reported)

    Visual analogue scale (self-reported)

    Time frame: Baseline, after treatment day 1 and day 3 of each week until Esketamine is ceased.

  2. Depressive symptoms assessed using the Beck Depression Inventory (BDI) 21-Item.

    Beck Depression Inventory (BDI) 21-Item.

    Time frame: Baseline and at week 4 after Esketamine was commenced.

  3. Anxiety symptoms assessed using the State-Trait Anxiety Inventory (STAI)

    State-Trait Anxiety Inventory (STAI)

    Time frame: Baseline and at week 4 after Esketamine was commenced.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2027, 49 months after the start.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 49 months is above that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2023
First posted
Oct 27, 2023
StartActual
Oct 31, 2023
Primary completionEst.
Dec 15, 2027
CompletionEst.
Aug 15, 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06103760
Lead sponsor
Royal North Shore Hospital
Responsible party
Gin Malhi (Professor, Royal North Shore Hospital) — Principal investigator
First posted
Oct 27, 2023
Start date
Oct 31, 2023
Primary completion
Dec 15, 2027 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Erica Bell
Contact
NSLHD-researchpoet@health.nsw.gov.au
02 9462 9905
Gin Malhi
principal investigator · Royal North Shore Hospital, University of Sydney

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion